These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 30949752

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
    Salas MQ, Mercadal S, Domingo Domenech E, Oliveira AC, Encuentra M, Climent F, Andrade Campos M, Aguilera C, Fernández de Sevilla A, Sureda A, González-Barca E.
    Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
    [Abstract] [Full Text] [Related]

  • 3. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
    Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.
    Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
    [Abstract] [Full Text] [Related]

  • 4. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.
    Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF, GELTAMO-IPI Project InvestigatorsDepartment of Translational Research, MD Anderson Cancer Centre, Madrid, Spain.Department of Pathology, MD Anderson Cancer Centre, Madrid, Spain..
    Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
    [Abstract] [Full Text] [Related]

  • 5. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.
    Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bjørn Poulsen C, Ortved Gang A, Brown P, El-Galaly TC, Larsen TS.
    Cancer Med; 2024 Jun; 13(12):e7239. PubMed ID: 38888359
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.
    Cui S, Xin W, Wang F, Shao X, Shao X, Niu R, Zhang F, Shi Y, Liu B, Gu W, Wang Y.
    BMC Cancer; 2024 Jul 25; 24(1):895. PubMed ID: 39054508
    [Abstract] [Full Text] [Related]

  • 8. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
    Bento L, Díaz-López A, Barranco G, Martín-Moreno AM, Baile M, Martín A, Sancho JM, García O, Rodríguez M, Sánchez-Pina JM, Novelli S, Salar A, Bastos M, Rodríguez-Salazar MJ, González de Villambrosia S, Córdoba R, García-Recio M, Martínez-Serra J, Del Campo R, Luzardo H, García D, Hong A, Abrisqueta P, Sastre-Serra J, Roca P, Rodríguez J, Gutiérrez A, Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO).
    Br J Haematol; 2020 Mar 25; 188(6):888-897. PubMed ID: 31782146
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ, Park SH, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, Kim MJ, Ahn JY, Hong J.
    J Clin Pathol; 2015 Sep 25; 68(9):733-8. PubMed ID: 25998512
    [Abstract] [Full Text] [Related]

  • 10. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL, Wei XL, Zhang YK, Hao XX, Huang WM, Wei Q, Wei YQ, Feng R.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):739-744. PubMed ID: 30369184
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H, Fan L, Fu D, Lin Q, Shen J.
    Ann Palliat Med; 2020 Jul 14; 9(4):1442-1452. PubMed ID: 32648457
    [Abstract] [Full Text] [Related]

  • 12. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.
    J Egypt Natl Canc Inst; 2011 Mar 14; 23(1):17-24. PubMed ID: 22099932
    [Abstract] [Full Text] [Related]

  • 13. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI, Park S, Kim JH, Kim HR, Kim M, Moon K, Seo J, Lee GW.
    Tumori; 2018 Aug 14; 104(4):292-299. PubMed ID: 29737944
    [Abstract] [Full Text] [Related]

  • 14. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.
    Am J Hematol; 2013 Apr 14; 88(4):273-6. PubMed ID: 23460351
    [Abstract] [Full Text] [Related]

  • 15. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D, Jelicic J, Trajkovic G, Balint MT, Bila J, Markovic O, Petkovic I, Nikolic V, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Mihaljevic B.
    Ann Hematol; 2018 Feb 14; 97(2):267-276. PubMed ID: 29130134
    [Abstract] [Full Text] [Related]

  • 16. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM.
    Ann Hematol; 2015 Nov 14; 94(11):1865-73. PubMed ID: 26327569
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX, Su LP.
    Zhonghua Zhong Liu Za Zhi; 2020 Nov 23; 42(11):949-954. PubMed ID: 33256307
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C.
    Oncotarget; 2016 Nov 22; 7(47):76934-76943. PubMed ID: 27764777
    [Abstract] [Full Text] [Related]

  • 19. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
    Jiang C, Ding C, Xu J, Teng Y, Chen J, Wang Z, Zhou Z.
    Clin Nucl Med; 2021 Jan 22; 46(1):1-7. PubMed ID: 33181743
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.